Back in April, Valeant made an initial offer backed by big shot hedge fund manager Bill Ackman for the Cramer-fave stock Allergan. The drug company has since fought tooth and nail to stay independent, even as Valeant has upped its bid twice.
Yet again, like a bad date who just won't take the hint, Valeant sent Allergan a letter on Monday morning indicating it might be willing to raise its bid again. Jim Cramer discussed the future of Allergan and its take on Valeant, with the company CEO, David Pyott.
"We have a huge momentum in sales growth. With 17 percent sales growth this quarter, it was the very best quarter in all of our 64 years as a company," said Pyott.